Table 2. Comparison of characteristics of patients with anti-tumor necrosis factor biologic associated psoriasis and idiopathic psoriasis.
| Characteristic | Anti-TNF associated psoriasis (n = 35) (%) |
Idiopathic psoriasis (n = 38) (%) |
p value |
|---|---|---|---|
|
Age at diagnosis (in
years) (Mean (SD) |
21 (10) | 37 (17) | < 0.001 |
| Gender | 0.59 | ||
| Male | 39 | 45 | |
| Female | 61 | 55 | |
| Race | 0.32 | ||
| White | 95 | 89 | |
| Black | 0 | 8 | |
| Hispanic | 5 | 0 | |
| Asian | 0 | 3 | |
| Native American | 0 | 0 | |
| IBD Type | 0.43 | ||
| UC | 24 | 32 | |
| CD | 76 | 63 | |
| IC | 0 | 5 | |
|
Disease Location
(CD only) |
0.05 | ||
| Ileal | 16 | 36 | |
| Colonic | 76 | 36 | |
| Ileocolonic | 8 | 28 | |
|
Disease behavior
(CD only) |
0.06 | ||
| Inflammatory | 39 | 72 | |
| Stricturing | 29 | 14 | |
| Penetrating | 32 | 14 | |
|
Perianal disease
(CD only) |
24 | 0 | 0.002 |
|
Disease extent –
Pancolitis (UC only) |
87 | 37 | 0.06 |
| TNF Exposure | |||
| Certolizumab pegol | 9 (22) | N/A | |
| Infliximab | 20 (49) | N/A | |
| Adalimumab | 12 (29) | N/A | |
| Psoriasis Type | |||
| Inverse | 6 (17) | 6 (16) | 0.90 |
| Guttate | 3 (9) | 0 (0) | N/A |
| Plaque | 18 (51) | 9 (24) | 0.01 |
| Palmoplantar | 5 (14) | 3 (8) | 0.41 |
| Nails | 0 (0) | 1 (3) | N/A |
| Scalp | 10 (29) | 17 (45) | 0.16 |